ALKERMES | ALKS - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 5.57B 2.9B 2026-03
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
ALKERMES USD 100.74M 4.1M 2025-09
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Coherus Biosciences USD -46.35M 90.86M 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Gilead Sciences USD 2.08B 1.56B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 135M 2026-03
J&J USD 7.82B 2.86B 2026-03
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Otsuka Holdings JPY 130.23B 54.96B 2026-03
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09